ONE: Healthcare IT Specialist - Bedside Manner Needs Work
Healthcare IT company trading at $0.24 vs $0.095 fair value. Strong recurring revenue model offset by execution risks and EMR competition. 60% overvalued.
View noteHealthcare IT company trading at $0.24 vs $0.095 fair value. Strong recurring revenue model offset by execution risks and EMR competition. 60% overvalued.
View noteGovernment software leader trading at 41.6x EBITDA vs 18.5x peers. Fair value $8.71 implies -55% downside. Strong moats face Microsoft threat.
View noteDevelopment-stage uranium leader with 3.10% ore grade advantage. Fair value $12.83 CAD vs current price, 82.7% projected EBITDA margins, binary regulatory catalyst November 2025.
View noteAustralia's #1 wealth platform with 89.2% ROIC trades at $37.14 vs $9.67 fair value. Exceptional margins face inevitable compression as competition intensifies.
View noteMining services contractor trading at $3.47 vs $5.96 fair value (72% upside). Strong order book visibility, conservative balance sheet, temporary OneSteel impacts clearing.
View noteHigh-risk exploration opportunity with 5,500 sq km Pilbara position, Northern Star partnership, and C$30.3M portfolio backing. Fair value C$0.138 vs C$0.10 current.
View noteNick Scali trades at $19.37 vs fair value $18.34, reflecting 5.6% overvaluation. Strong ANZ market leadership with UK expansion catalyst requiring selective entry timing.
View noteHOLD rating with $3.25 fair value vs $4.49 current price. Strong trophon franchise but CORIS execution risk at 28% premium valuation.
View noteAVOID rating with fair value $4.20 vs current $14.82. Strong 19% revenue growth and 95% recurring revenue model undermined by extreme 253% overvaluation and cloud disintermediation risk.
View noteHOLD rating with $13.07 fair value vs $10.94 current price. Partnership income surged 202% to 38% of profit. 6.7% dividend yield with transformation execution risk.
View noteHOLD rating with $0.40 fair value vs $0.37 current price. Strong 20.5% ROIC and underground expansion offset by peak cycle positioning and execution risks.
View noteLycopodium trades at $12.00 vs fair value $16.62, offering 38.5% upside through technical differentiation, SAXUM integration, and critical minerals recovery with 32.8% ROIC.
View note